CA2090234C - Method for providing improved analgesic effect - Google Patents
Method for providing improved analgesic effectInfo
- Publication number
- CA2090234C CA2090234C CA002090234A CA2090234A CA2090234C CA 2090234 C CA2090234 C CA 2090234C CA 002090234 A CA002090234 A CA 002090234A CA 2090234 A CA2090234 A CA 2090234A CA 2090234 C CA2090234 C CA 2090234C
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- medicament
- alkyl
- cycloalkyl
- cycloalkylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A method for providing improved analgesic and/or anti-inflammatory effect by adm inistering a safe and effective amount of a composition comprising a naphthalene derivative along with a sympathomimeti c amine.
Description
W O 92/04021 2 0 9 Q 2 3 4 PC~r/US91/06398 METHOD FOR PROVIDING IMPROVED ANALGESIC E;FECT
TECHNICAL FIELD
The present invention relates to a method for providing improvea analgesic and/or anti-inflammatory effect by administering a safe and effective amount of a composition comprising a naphthalene derivative a7ong with a sympathomimetic amine.
BACKGROUND OF THE INVENTION
Inflammation, or the "inflammatory response", is the result of comDIex interconnected physiological events, including increased vascular permeability. fluid accumulations. and the migration of a cnanging population of inflammatory cells into the inflamed area The clinical manifestations of inf7ammation lnclude swelling (eaema)~
increased local temperature, erythema, anG pain. The inflammatory response can be triggered by any of a number of causative factors, including certain bacteria, radiation, hypersensitivity to chemical agents, arthritis-like conditions, and the like. The inflammatory response is generally believed to be a primary defense mechanism in the body, but, unchecked, can become excessive and can result in functional impairment.
The use of non-steroidal anti-inflammatory, anti-pyretic and analaesic drugs, especially the salicylates. which include aspirin and asDirin derivatives. to combat inflammation and attendant cain l, acceDted meaical practice. The non-steroidals are commonlv emplovea ,; tO relieve Dain and inflammation associated with, for example. bursit-is. arthritis, and the like.
While pain is incapable of precise definition due to its Dasical-ly subjective nature, it can generally be said that the term refers to feelings of distress or suffering caused by stimulation of sDecialized nerve endings. A great variety of drugs have been developed to reduce pain in man and other animals; some directed to eliminating pain at its source. and others directed to blocking the perception of pain Dy the Drain. Among the latter group of drugs that are designed to block the sensation of pain, are the analgesics. which generally relieve ~; pain without causing unconsciousness. Analgesics can be further classified into two main categories: opioid analgesics. including morphine. codeine. levorphanol, and the morphine-like analgesics 2 G 9 ~ 2 3 4 PCr/US91/06398 merperidine, and methadone; and antipyretic analgesics, such as aspirin, ibuprofen, phenacetin, acetaminophen, phenylbutazone, and indomethacin.
Although the precise pharmacological action of these analgesics is uncertain, there are certain effects which readily distinguish the opioid analgesics from the antipyretics. In particular, the antipyre-tics are weak analgesics, with much of their effect in the peripheral nervous system, so that behavioral changes do not usually occur.
Generally, these analgesics relieve only pain originating from mus-cles, joints, tendons and fasciae, and are ineffective against deep visceral pain. However, the opioid analgesics are quite effective against all types of pain, with broad-based action in the central nervous system. Aside from potent analgesia, the opioids, also known as narcotics, often produce effects on mood and other behavioral changes. Perhaps the most notable side effect of opioid analgesics is the fact that their repeated use is associated with tolerance, as well as psychic and physical dependence.
Naproxen ((+)-2-(6~-methoxy-naphthyl) propionic acid), a non-steroidal anti-inflammatory drug (NSAID), became available in the U.S.
for the treatment of rheumatoid arthritis in 1976. Naproxen has been further indicated for osteoarthritis, tendonitis and bursitis, anky-losing spondylitis and acute gout. Additional indications include mild to moderate pain and primary dysmenorrhea. Naproxen has also been demonstrated to have less severe gastrointestinal and central nervous system adverse effects than aspirin.
The use of naproxen, as well as other of the newer non-steroidal anti-inflammatory agents (i.e., excluding aspirin, acetaminophen and phenacetin) in the preparation of cough/cold pharmaceutical composi-tions containing sympathomimetic amines, has been disclosed in, for example, U.S. Patent 4,552,899 to Sunshine et al. issued November 12, 1985.
Surprisingly, the present inventor has found that selected compositions comprising certain naphthalene derivatives in combination with sympathomimetic amines provide improved analgesic and~or anti-3~ inflammatory effect.
W O 92/04021 2 0 9 0 2 3 4 PC~r/US91/06398 SUMMARY OF THE INVENTION
The present invention relates to a method of eliciting a sus-tained, enhanced analgesic response in a human or lower animal in need of such treatment, comprising administering to such human or lower animal a safe and effective amount of a composition comprising:
a) from about 10% to about 95% of a carboxylic acid represented by the following formula:
R~
(I) R~ is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, tri-fluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methyl-ene; and R' is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopen-tylethyl having from S to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from about S~O to about 90% of one or more of a sympatho-mimetic amine.
All percentages and ratios used herein are by weight unless otherwise indicated.
W 0 92/04021 2n~0234 PC~r/US91/06398 DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of eliciting a sustain-ed, enhanced analgesic response in a human or lower animal in need of such treatment, comprising administering to such human or lower animal a safe and effective amount of a composition comprising a naphthalene derivative, preferably a 2-(6'-substituted-2'-naphthyl)-acetic acid derivative, and salts and esters thereof along with a sympathomimetic amine.
The naphthalene derivatives of this invention are the carboxylic acids and carboxylic acid esters represented by the following formula, and the pharmaceutically acceptable salts of the carboxylic acids represented by the following formula:
¦ ~ ~ ~ 4 (I) In the above formula, R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, tri-fluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms. alkoxymethylthio having up to 7 carbon atoms, cyano difluoromethylthio, phenyl or alkylsub-stituted phenyl having up to 8 carbon atoms;
one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene;
R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl.
W O 92/04021 2 0 9 ~ 2 3 g PC~r/US91/06398 Preferably7 the 6'-substituent (represented by R1 in the above formula) is methyl, ethyl, isopropyl, cyclopropyl, trifluoromethyl, vinyl, ethynyl, fluoro, chloro, methoxy, ethoxy, methoxymethyloxy, difluoromethoxy, methylthio, ethylthio, methoxymethylthio, difluoro-S methylthio or phenyl; one of R2 and R3 is hydrogen and the other ismethyl; and R' is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, pentyl. isopentyl, hexyl, 2-hexyl, isohexyl, heptyl, isoheptyl, octyl, isooctyl, nonyl, isononyl, decyl, isodecyl, undecyl, dodecyl, tri-decyl, tetradecyl, pentadecyl, hexadecyl, cyclopentyl or cyclohexyl.
The term "alkyl" refers to and includes branched and straight chain hydrocarbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, tertiary-butyl, neopentyl, isopentyl. hexyl, octyl, nonyl, isodecyl, 6-methyldecyl, tridecyl, isotetradecyl, Dentadecyl, isohexadecyl, heptadecyl, eicosyl, docosyl, and the like.
The term "unsaturated alkyl" refers to unsaturated hydrocarbon groups such as vinyl, allyl, propenyl, crotyl, isopropenyl, 2-propynyl, l-propenyl, 2-butenyl, 1,3-butadienyl, 2-pentenyl, 2-penten-4-ynyl and the like.
The term "cycloalkyl" refers to cyclo hydrocarbon groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
The term "alkoxy" refers to straight or branched chain alkyl ether groups such as methoxy, ethoxy, 2-propoxy, butoxy, 3-pentoxy and the like.
The term "alkoxymethyloxy" refers to methyl ether groups substi-tuted with one alkoxy group (defined above) such as methoxymethyloxy, ethoxymethloxy, isopropoxymethyloxy and the like.
The term ~alkylthio" refers to straight or branched chain alkyl-thio ether groups such an methylthio, ethylthio, propylthio. 2-propyl-thio, 2-butylthio, pentylthio, 3-hexylthio and the like.
The term "alkylthiomethyloxy" refers to methyl ether groups substituted with an alkylthio group (defined above) such as methyl-thiomethyloxy, 2-propylthiomethyloxy, pentylthiomethloxy and the like.
The term "alkylthiomethylthio" as used herein denoted methylthio ether groups substituted with an alkylthio group such as methylthio-methylthio, ethylthiomethylthio and the like.
WO 92/0402] 2 ~ PCI/US91/06398 , .
The term "alkoxymethylthio" refers to methylthio ether groups substituted with an alkoxy group such as methoxymethylthio, ethoxy-methylthio, 2-propoxymethylthio and the like.
The term "aryl" refers to phenyl, or o-, m- and/or p- alkylsub-stituted phenyl derivatives such as phenyl, o-tolyl, m-tolyl, p-tolyl, o-ethylphenyl, m-ethylphenyl, p-ethylphenyl, xylyl and the like.
The term "cycloalkylmethyl" refers to cycloalkyl substituted methyl groups such as cyclopropylmethyl, cyclobutylmethy, cyclopentyl-methyl, cyclohexylmethyl, cycloheptylmethyl, and the like. The term "2-cycloalkylethyl" refers to an ethyl group substituted at the 2-position with a cycloalkyl group such as 2-cyclopropylethyl, 2-cy-clobutylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl and 2-cyclo-heptylethyl.
The most preferred compound used herein is (+)-2-(6~-methoxy-2-napthyl) propionic acid, and salts and esters thereof.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from nonorganic bases include sodium, potassium, lithium, ammonia, calcium, magnesium, ferrous, zinc, manganous, aluminum, ferric, manganic salts and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, tertiary and quater-nary amines, substituted amines including naturally occurring substi-tuted amines, cyclic amines and basic ion exchange resins, such as triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylamino-ethanol, lysine, arginine, histidine, caffeine, procaine, N-ethylpip-eridine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purines, piperazine, piperidine, poly-amine resins and the like.
When one of R2 and R3 is hydrogen and the other is methyl or difluoromethyl, the compounds of Formula 1 exist as pairs of enantio-morphs or optical isomers. Each enantiomorph and mixtures thereof are included within the present invention. The compounds of Formula which exist as pairs of enantiomorphs can be administered as racemic mixtures or they can be administered as resolved enantiomorphs. In WO g2/040'1 PCr/US91~06398 -7- 2q9 023 4 some instances. one enantiomorph exhibits greater anti-inflammatory, analgesic and/or anti-pyretic activity than the other corresponding enantiomorph. The most preferred derivatives for use herein are the S(+)enantiomorphs.
The optical isomers can be resolved by conventional means, such as selective biological degradation or by the preparation of dias-tereo-isomeric salts of the naphthalene derivative with an optically active amine base such as cinchonidine and separating the diastereoisomers by fractional crystallization. The separated diastereoisomeric salts are then acid cleaved to yield the respective optical isomer.
These comDounds are fully disclosed in U.S. Patent 3,904,682 to Fried et al. issued September 9, 1975 and in U.S. Patent 3,g98,966 to Fried et al. issued OecemDer 21, 1976 as having ant~ n~ ~ alol ~, analgesic and anti-pyretic activities and as being useful in the treatment and elimination of inflammation, such as rheumatism, concussion, laceration, arthritis, bone fractures, post-traumatic conditions, and gout.
Sympathomimetic amines are a well-known class of drugs which activate adrenergic receptors. These drugs are fully described in ResDiratorY Pharmacolo~Y and TheraDeutics, Ziment, ~.B., Saunders Company (1978), pp. 316-33g. Dnugs that are particularly prdf~,.~ for use herein are those which are known to stimulate the alpha adrenergic receotors.
The sympathomimetic amines useful herein include pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine, their pharma-ceutically acceptable salts, and mixtures t~ereof.
Preferably, the pharmaceutical composZ.tions of the present invention comprise the naphthalene derivative and sympathomimetic amine in a ratio of naphthalene derivative:sympathomimetic amine of from about 200:1 to about 1:1, preferably from about 50:1 to about 1:1 and most preferably from about 10:1 to about 1:1.
Various oral dosage forms can be used, including such solid forms as tablets, gelcaps capsules, granules, lozenges and bulk powders and liquid forms such as syrups and suspensions. These oral forms com-prise a safe and effective amount, usually at least about 5% of the active component. Solid oral dosage forms preferably contain from about 5% to about 95%, more preferably from about 107. to about 95%.
, WO 92/04021 PCr/US91/06398 20q 0234 -a-and most preferably from about 25% to about 95% of the active compo-nent. Liquid oral dosage forms preferably contatn from about 1% to about 50% and more preferably from about 1% to about 25% and most preferably from about 3% to about 10% of the active component.
Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, preservatives and flow-inducing agents.
Liquid oral dosage forms include aqueous and nonaqueous solu-tions, emulsions, suspensions, and solutions and/or suspensions reconstituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, and flavoring agents. Specific examples of pharmaceutically acceptable carriers and excipients that !S may be used to formulate oral dosage forms, are described in U.S.
Patent 3,903,29~, Robert, issued September 2, 1915.
Techniques and C~ ~ S~;QI)S for making solid or~
dosage forms are described in Marshall, ~Solid Oral Oosage Forms,"
Modern Pharmaceutics, Vol. 7, (Banker and Rhodes, editors), 359-42J
(1979). T~chniques and c~",~u~ "s for making tablets (compressed and molded), capsules (hard and soft gelatin) and pills are described in Reminaton's Pharmaceutical Scienc-es (Arthur Osol, editor), 1553-1593 (1980).
In preparing the liquid oral dosage forms, the active component is incorporated into an aqueous-based orally acceptable pharmaceutical carrier consistent with con~entional pharmaceutical practices. An "aqueous-based orally acceptable pharmaceutical carrier" is one wherein the entire or predominant solvent content is water. Typical carriers include simple aqueous solutions, syrups, dispersions and suspensions, and aqueous based emulsions such as the oil-in-water type. The most preferred carrier is a suspension of the pharma-ceutical composition in an aqueous vehicle containing a suitable suspending agent. Suitable suspending agents include Avicel RC-591 (a microcrystalline cellulose/sodium carboxymethyl cellulose mixture ~ .~
WO 92/04021 j PCr/US91/06398 available from FMC), guar gum and the like. Such suspending agents are well known to those skilled in the art. While the amount of water in the compositions of this invention can vary over quite a wide range depending upon the total weight and vo!ume of the active component and S other optional non-active ingredients, the total water content, based on the weight of the final composition, will generally range from about 20 to about 75%, and, preferably, from about 20 to about ~0%, by weight/volume.
Although water itself may make up the entire carrier, typical liquid formulations preferably contain a co-solvent, for example, propylene glycol, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients, such as flavoring oils and the like into the composition. In general, therefore, the compositions of this invention preferably contain from lS about 5 to about 25 volume/volume percent and, most preferably, from about 10 to about 20 volume/ volume percent, of the co-solvent.
The compositions of this invention may optionally contain one or more other known therapeutic agents, particularly those commonly utilized in cough/cold preparations, such as, for example, a cough suppressant such as dextromethorphan, chlophedianol, carbetapentane.
caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, their pharmaceutically-acceptable salts; an expectorant or mucolytic such as glyceryl guaiacolate, terpin~
ammonium chloride. N-acetylcysteine and bromhexine, ambroxol. their pharmaceutically acceptable salts; and an antihistamine such as chlorpheniramine brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenhydramine, phenindamine, pyrilamine, azatadine, their pharmaceutically acceptable salts, as well as the non-sedating antihistamines which include acrivastine, AHR-11125, phenindamine. astemizole, azelastine. cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine, and terfenadine, their pharmaceutically acceptable salts: all of these components, as well as their acceptable dosage ranges are described in the following:
U.S. Patent 4,183,465 to Sunshine et al., issued November 8. 1988.
U.S. Patent 4,619,g34 to Sunshine et al., issued October 28, 1986.
, WO 92/04021 f PCr/lJ'S91/O~i398 209023 4 -lO-Also useful are ~r~i ,c~,odilators such as l~ le~,cl ,~lline and albuterol. A highly prefer.~d o~ al c~",~nent is ca~f~;ne which is pr~ter~l~ly presen~ at a level of from about 10% to about 5096.
Other optional ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants and the like to provide a palatable and pleasant looking final prod-uct, antioxidants, for example, butylated hydroxy anisole or butylated IO hydroxy toluene, and preservatives, for example, methyl or propyl paraben or sodium benzoate, to prolong and enhance shelf life.
ME~HOD OF T~EATMENT
The amount of the pharmaceutical composition administered depends upon the percent of active ingredients within its formula, which is a IS function of the amount of the naphthalene derivative and any optional componènts such as a decongestant, expectorant and/or antihistamine required per dose, stability, release characteristics and other pharmaceutical parameters.
Usually from about I mg/kg to about 50 mgtkg per day, preferably from about 2 mg/kg to about 30 mg/kg per day and most preferably from about 3 mg/kg per day to about 20 mg~kg per day of the pharmaceutical composition is administered as described herein. This amount can be given in a single dose, or, preferably, in multiple (two to six) doses repeatedly or sustained release dosages over ~he course of treatment.
Generally, each individual dosage of the pharmaceutical comDositions of the present invention range from about I mg/kg to about 25 mg/kg, preferably from about 2 mg/kg to about 15 mg/kg and most preferably from about 3 mg/kg to about IO mg/kg. Typical unit dosage forms for oral auministration generally comprise from about IOO mg to about 2000 mg, preferably from about I50 mg to about 600 mg and most preferably from about I50 mg to about 400 mg of the naphthalene derivative.
While dosages higher than the foregoing are effective to provide relief from cough, cold-like~ flu and flu-like symptoms, care must be taken, as with any drug, in some individuals to prevent adverse side effects.
The fo110wing examples illustrate embodiments of the subject invention wherein both essential and optional ingredients are com-bined.
W O 92/04021 2 0 ~ ~ 2 3 4 Pc~r/usgl/06398 EXAMPLE I
A soft gelatin capsule composition for oral administration is prepared by combining the following ingredients:
Inqredient Amount Naproxen 200 mg Pseudoephedrine HCl 30 mg Triturate active ingredients and q.s. with lactose to selected capsule size.
Administration of two of the above capsules to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE II
A soft gelatin capsule composition for oral administration is prepared by combining the following ingredients:
In~redient Amount Naproxen 200 mg Astemizole 10 mg Pseudoephedrine HCL 30 mg Glyceryl guaiacolate 100 mg Triturate active ingredients and q.s. with lactose to selected capsule size.
Administration of two of the above capsules to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE III
A liquid composition for oral administration is prepared by combining the following ingredients:
Ingredient YO W/V
Naproxen 6.667 Pseudoephedrine HCl 0.200 Alcohol (95X) 25.000 Propylene Glycol 25.000 Sodium Citrate 2.000 Citric Acid 0.250 Liquid Sugar 70.000 Glycerin 7.000 Colorants 0.008 Flavor 0.500 Water, Purified QS 100.000 WO 92/04021 2 ~) 9 ~) 2 3 ~1 PCr/US91/06398 The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid and Pseudoephedrine HCI are added sequen-tially and dissolved with agitation. The glycerin and liquid sugar are then added. In a seperate container the colorance are added to purified water (approximately 0.5% of the final batch volume). This colorance solution is then added to the first batch container. In a seperate container the naproxen is added to the alcohol while stir-ring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.
Administration of 30 ml to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE IV
A liquid composition for oral administration is prepared by combining the following ingredients:
Inqredient % W/V
Naproxen 6.667 Pseudoephedrine HCl 0.200 Chlorpheniramine Maleate 0.013 Alcohol (95~.) 25.000 Propylene Glycol 25.000 Sodium Citrate 2.000 Citric Acid 0.250 Liquid Sugar 70.000 Glycerin 7.000 Colorants 0.008 Flavor O.S00 Water, Purified QS100.000 The purified water (approximately 10Z of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, pseudoephedrine HCI and chlorpheniramine maleate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a seperate container the colorance are added to purified water ~approximately 0.5% of the final WO 92/04021 PCr/US91/06398 batch volume). This colorance solution is then added to the first batch container. In a seperate container the naproxen is added to the alcohol while stirring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homo-geneous and then added to the first container. The remaining purifiedwater is added to the resulting mixture and stirred.
Administration of 30 ml to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE V
A liquid composition for oral administration is prepared by combining the following ingredients:
Inqredient 7O W/V
Naproxen 6.667 1; Pseudoephedrine HCl 0.200 Chlorpheniramine Maleate 0.013 Dextromethorphan HBr 0.100 Alcohol (95%) 25.000 Propylene Glycol 25.000 Sodium Citrate 2.000 Citric Acid 0.250 Liquid Sugar 70.000 Glycerin ~ 7.000 Colorants 0.008 Flavor 0 500 Water, Purified ~S 100.000 The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, pseudoephedrine HCI and chlorpheniramine maleate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a seperate container the colorance are added to purified water (approximately 0.5% of the final batch volume). This colorance solution is then added to the first batch container. In a sepera~e container the naproxen and dextro-methorphan HBr are added sequentially to the alcohol while stirring.
L~
W O 92/04021 ~ PC~r/~S91/0~98 2 0 q 0 2 3 4 14 The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.
, Administration of 30 ml to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
TECHNICAL FIELD
The present invention relates to a method for providing improvea analgesic and/or anti-inflammatory effect by administering a safe and effective amount of a composition comprising a naphthalene derivative a7ong with a sympathomimetic amine.
BACKGROUND OF THE INVENTION
Inflammation, or the "inflammatory response", is the result of comDIex interconnected physiological events, including increased vascular permeability. fluid accumulations. and the migration of a cnanging population of inflammatory cells into the inflamed area The clinical manifestations of inf7ammation lnclude swelling (eaema)~
increased local temperature, erythema, anG pain. The inflammatory response can be triggered by any of a number of causative factors, including certain bacteria, radiation, hypersensitivity to chemical agents, arthritis-like conditions, and the like. The inflammatory response is generally believed to be a primary defense mechanism in the body, but, unchecked, can become excessive and can result in functional impairment.
The use of non-steroidal anti-inflammatory, anti-pyretic and analaesic drugs, especially the salicylates. which include aspirin and asDirin derivatives. to combat inflammation and attendant cain l, acceDted meaical practice. The non-steroidals are commonlv emplovea ,; tO relieve Dain and inflammation associated with, for example. bursit-is. arthritis, and the like.
While pain is incapable of precise definition due to its Dasical-ly subjective nature, it can generally be said that the term refers to feelings of distress or suffering caused by stimulation of sDecialized nerve endings. A great variety of drugs have been developed to reduce pain in man and other animals; some directed to eliminating pain at its source. and others directed to blocking the perception of pain Dy the Drain. Among the latter group of drugs that are designed to block the sensation of pain, are the analgesics. which generally relieve ~; pain without causing unconsciousness. Analgesics can be further classified into two main categories: opioid analgesics. including morphine. codeine. levorphanol, and the morphine-like analgesics 2 G 9 ~ 2 3 4 PCr/US91/06398 merperidine, and methadone; and antipyretic analgesics, such as aspirin, ibuprofen, phenacetin, acetaminophen, phenylbutazone, and indomethacin.
Although the precise pharmacological action of these analgesics is uncertain, there are certain effects which readily distinguish the opioid analgesics from the antipyretics. In particular, the antipyre-tics are weak analgesics, with much of their effect in the peripheral nervous system, so that behavioral changes do not usually occur.
Generally, these analgesics relieve only pain originating from mus-cles, joints, tendons and fasciae, and are ineffective against deep visceral pain. However, the opioid analgesics are quite effective against all types of pain, with broad-based action in the central nervous system. Aside from potent analgesia, the opioids, also known as narcotics, often produce effects on mood and other behavioral changes. Perhaps the most notable side effect of opioid analgesics is the fact that their repeated use is associated with tolerance, as well as psychic and physical dependence.
Naproxen ((+)-2-(6~-methoxy-naphthyl) propionic acid), a non-steroidal anti-inflammatory drug (NSAID), became available in the U.S.
for the treatment of rheumatoid arthritis in 1976. Naproxen has been further indicated for osteoarthritis, tendonitis and bursitis, anky-losing spondylitis and acute gout. Additional indications include mild to moderate pain and primary dysmenorrhea. Naproxen has also been demonstrated to have less severe gastrointestinal and central nervous system adverse effects than aspirin.
The use of naproxen, as well as other of the newer non-steroidal anti-inflammatory agents (i.e., excluding aspirin, acetaminophen and phenacetin) in the preparation of cough/cold pharmaceutical composi-tions containing sympathomimetic amines, has been disclosed in, for example, U.S. Patent 4,552,899 to Sunshine et al. issued November 12, 1985.
Surprisingly, the present inventor has found that selected compositions comprising certain naphthalene derivatives in combination with sympathomimetic amines provide improved analgesic and~or anti-3~ inflammatory effect.
W O 92/04021 2 0 9 0 2 3 4 PC~r/US91/06398 SUMMARY OF THE INVENTION
The present invention relates to a method of eliciting a sus-tained, enhanced analgesic response in a human or lower animal in need of such treatment, comprising administering to such human or lower animal a safe and effective amount of a composition comprising:
a) from about 10% to about 95% of a carboxylic acid represented by the following formula:
R~
(I) R~ is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, tri-fluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methyl-ene; and R' is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopen-tylethyl having from S to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from about S~O to about 90% of one or more of a sympatho-mimetic amine.
All percentages and ratios used herein are by weight unless otherwise indicated.
W 0 92/04021 2n~0234 PC~r/US91/06398 DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of eliciting a sustain-ed, enhanced analgesic response in a human or lower animal in need of such treatment, comprising administering to such human or lower animal a safe and effective amount of a composition comprising a naphthalene derivative, preferably a 2-(6'-substituted-2'-naphthyl)-acetic acid derivative, and salts and esters thereof along with a sympathomimetic amine.
The naphthalene derivatives of this invention are the carboxylic acids and carboxylic acid esters represented by the following formula, and the pharmaceutically acceptable salts of the carboxylic acids represented by the following formula:
¦ ~ ~ ~ 4 (I) In the above formula, R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, tri-fluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms. alkoxymethylthio having up to 7 carbon atoms, cyano difluoromethylthio, phenyl or alkylsub-stituted phenyl having up to 8 carbon atoms;
one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene;
R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl.
W O 92/04021 2 0 9 ~ 2 3 g PC~r/US91/06398 Preferably7 the 6'-substituent (represented by R1 in the above formula) is methyl, ethyl, isopropyl, cyclopropyl, trifluoromethyl, vinyl, ethynyl, fluoro, chloro, methoxy, ethoxy, methoxymethyloxy, difluoromethoxy, methylthio, ethylthio, methoxymethylthio, difluoro-S methylthio or phenyl; one of R2 and R3 is hydrogen and the other ismethyl; and R' is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, pentyl. isopentyl, hexyl, 2-hexyl, isohexyl, heptyl, isoheptyl, octyl, isooctyl, nonyl, isononyl, decyl, isodecyl, undecyl, dodecyl, tri-decyl, tetradecyl, pentadecyl, hexadecyl, cyclopentyl or cyclohexyl.
The term "alkyl" refers to and includes branched and straight chain hydrocarbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, tertiary-butyl, neopentyl, isopentyl. hexyl, octyl, nonyl, isodecyl, 6-methyldecyl, tridecyl, isotetradecyl, Dentadecyl, isohexadecyl, heptadecyl, eicosyl, docosyl, and the like.
The term "unsaturated alkyl" refers to unsaturated hydrocarbon groups such as vinyl, allyl, propenyl, crotyl, isopropenyl, 2-propynyl, l-propenyl, 2-butenyl, 1,3-butadienyl, 2-pentenyl, 2-penten-4-ynyl and the like.
The term "cycloalkyl" refers to cyclo hydrocarbon groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
The term "alkoxy" refers to straight or branched chain alkyl ether groups such as methoxy, ethoxy, 2-propoxy, butoxy, 3-pentoxy and the like.
The term "alkoxymethyloxy" refers to methyl ether groups substi-tuted with one alkoxy group (defined above) such as methoxymethyloxy, ethoxymethloxy, isopropoxymethyloxy and the like.
The term ~alkylthio" refers to straight or branched chain alkyl-thio ether groups such an methylthio, ethylthio, propylthio. 2-propyl-thio, 2-butylthio, pentylthio, 3-hexylthio and the like.
The term "alkylthiomethyloxy" refers to methyl ether groups substituted with an alkylthio group (defined above) such as methyl-thiomethyloxy, 2-propylthiomethyloxy, pentylthiomethloxy and the like.
The term "alkylthiomethylthio" as used herein denoted methylthio ether groups substituted with an alkylthio group such as methylthio-methylthio, ethylthiomethylthio and the like.
WO 92/0402] 2 ~ PCI/US91/06398 , .
The term "alkoxymethylthio" refers to methylthio ether groups substituted with an alkoxy group such as methoxymethylthio, ethoxy-methylthio, 2-propoxymethylthio and the like.
The term "aryl" refers to phenyl, or o-, m- and/or p- alkylsub-stituted phenyl derivatives such as phenyl, o-tolyl, m-tolyl, p-tolyl, o-ethylphenyl, m-ethylphenyl, p-ethylphenyl, xylyl and the like.
The term "cycloalkylmethyl" refers to cycloalkyl substituted methyl groups such as cyclopropylmethyl, cyclobutylmethy, cyclopentyl-methyl, cyclohexylmethyl, cycloheptylmethyl, and the like. The term "2-cycloalkylethyl" refers to an ethyl group substituted at the 2-position with a cycloalkyl group such as 2-cyclopropylethyl, 2-cy-clobutylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl and 2-cyclo-heptylethyl.
The most preferred compound used herein is (+)-2-(6~-methoxy-2-napthyl) propionic acid, and salts and esters thereof.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from nonorganic bases include sodium, potassium, lithium, ammonia, calcium, magnesium, ferrous, zinc, manganous, aluminum, ferric, manganic salts and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, tertiary and quater-nary amines, substituted amines including naturally occurring substi-tuted amines, cyclic amines and basic ion exchange resins, such as triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylamino-ethanol, lysine, arginine, histidine, caffeine, procaine, N-ethylpip-eridine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglycamine, theobromine, purines, piperazine, piperidine, poly-amine resins and the like.
When one of R2 and R3 is hydrogen and the other is methyl or difluoromethyl, the compounds of Formula 1 exist as pairs of enantio-morphs or optical isomers. Each enantiomorph and mixtures thereof are included within the present invention. The compounds of Formula which exist as pairs of enantiomorphs can be administered as racemic mixtures or they can be administered as resolved enantiomorphs. In WO g2/040'1 PCr/US91~06398 -7- 2q9 023 4 some instances. one enantiomorph exhibits greater anti-inflammatory, analgesic and/or anti-pyretic activity than the other corresponding enantiomorph. The most preferred derivatives for use herein are the S(+)enantiomorphs.
The optical isomers can be resolved by conventional means, such as selective biological degradation or by the preparation of dias-tereo-isomeric salts of the naphthalene derivative with an optically active amine base such as cinchonidine and separating the diastereoisomers by fractional crystallization. The separated diastereoisomeric salts are then acid cleaved to yield the respective optical isomer.
These comDounds are fully disclosed in U.S. Patent 3,904,682 to Fried et al. issued September 9, 1975 and in U.S. Patent 3,g98,966 to Fried et al. issued OecemDer 21, 1976 as having ant~ n~ ~ alol ~, analgesic and anti-pyretic activities and as being useful in the treatment and elimination of inflammation, such as rheumatism, concussion, laceration, arthritis, bone fractures, post-traumatic conditions, and gout.
Sympathomimetic amines are a well-known class of drugs which activate adrenergic receptors. These drugs are fully described in ResDiratorY Pharmacolo~Y and TheraDeutics, Ziment, ~.B., Saunders Company (1978), pp. 316-33g. Dnugs that are particularly prdf~,.~ for use herein are those which are known to stimulate the alpha adrenergic receotors.
The sympathomimetic amines useful herein include pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine, their pharma-ceutically acceptable salts, and mixtures t~ereof.
Preferably, the pharmaceutical composZ.tions of the present invention comprise the naphthalene derivative and sympathomimetic amine in a ratio of naphthalene derivative:sympathomimetic amine of from about 200:1 to about 1:1, preferably from about 50:1 to about 1:1 and most preferably from about 10:1 to about 1:1.
Various oral dosage forms can be used, including such solid forms as tablets, gelcaps capsules, granules, lozenges and bulk powders and liquid forms such as syrups and suspensions. These oral forms com-prise a safe and effective amount, usually at least about 5% of the active component. Solid oral dosage forms preferably contain from about 5% to about 95%, more preferably from about 107. to about 95%.
, WO 92/04021 PCr/US91/06398 20q 0234 -a-and most preferably from about 25% to about 95% of the active compo-nent. Liquid oral dosage forms preferably contatn from about 1% to about 50% and more preferably from about 1% to about 25% and most preferably from about 3% to about 10% of the active component.
Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, preservatives and flow-inducing agents.
Liquid oral dosage forms include aqueous and nonaqueous solu-tions, emulsions, suspensions, and solutions and/or suspensions reconstituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, and flavoring agents. Specific examples of pharmaceutically acceptable carriers and excipients that !S may be used to formulate oral dosage forms, are described in U.S.
Patent 3,903,29~, Robert, issued September 2, 1915.
Techniques and C~ ~ S~;QI)S for making solid or~
dosage forms are described in Marshall, ~Solid Oral Oosage Forms,"
Modern Pharmaceutics, Vol. 7, (Banker and Rhodes, editors), 359-42J
(1979). T~chniques and c~",~u~ "s for making tablets (compressed and molded), capsules (hard and soft gelatin) and pills are described in Reminaton's Pharmaceutical Scienc-es (Arthur Osol, editor), 1553-1593 (1980).
In preparing the liquid oral dosage forms, the active component is incorporated into an aqueous-based orally acceptable pharmaceutical carrier consistent with con~entional pharmaceutical practices. An "aqueous-based orally acceptable pharmaceutical carrier" is one wherein the entire or predominant solvent content is water. Typical carriers include simple aqueous solutions, syrups, dispersions and suspensions, and aqueous based emulsions such as the oil-in-water type. The most preferred carrier is a suspension of the pharma-ceutical composition in an aqueous vehicle containing a suitable suspending agent. Suitable suspending agents include Avicel RC-591 (a microcrystalline cellulose/sodium carboxymethyl cellulose mixture ~ .~
WO 92/04021 j PCr/US91/06398 available from FMC), guar gum and the like. Such suspending agents are well known to those skilled in the art. While the amount of water in the compositions of this invention can vary over quite a wide range depending upon the total weight and vo!ume of the active component and S other optional non-active ingredients, the total water content, based on the weight of the final composition, will generally range from about 20 to about 75%, and, preferably, from about 20 to about ~0%, by weight/volume.
Although water itself may make up the entire carrier, typical liquid formulations preferably contain a co-solvent, for example, propylene glycol, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients, such as flavoring oils and the like into the composition. In general, therefore, the compositions of this invention preferably contain from lS about 5 to about 25 volume/volume percent and, most preferably, from about 10 to about 20 volume/ volume percent, of the co-solvent.
The compositions of this invention may optionally contain one or more other known therapeutic agents, particularly those commonly utilized in cough/cold preparations, such as, for example, a cough suppressant such as dextromethorphan, chlophedianol, carbetapentane.
caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, their pharmaceutically-acceptable salts; an expectorant or mucolytic such as glyceryl guaiacolate, terpin~
ammonium chloride. N-acetylcysteine and bromhexine, ambroxol. their pharmaceutically acceptable salts; and an antihistamine such as chlorpheniramine brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenhydramine, phenindamine, pyrilamine, azatadine, their pharmaceutically acceptable salts, as well as the non-sedating antihistamines which include acrivastine, AHR-11125, phenindamine. astemizole, azelastine. cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine, and terfenadine, their pharmaceutically acceptable salts: all of these components, as well as their acceptable dosage ranges are described in the following:
U.S. Patent 4,183,465 to Sunshine et al., issued November 8. 1988.
U.S. Patent 4,619,g34 to Sunshine et al., issued October 28, 1986.
, WO 92/04021 f PCr/lJ'S91/O~i398 209023 4 -lO-Also useful are ~r~i ,c~,odilators such as l~ le~,cl ,~lline and albuterol. A highly prefer.~d o~ al c~",~nent is ca~f~;ne which is pr~ter~l~ly presen~ at a level of from about 10% to about 5096.
Other optional ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants and the like to provide a palatable and pleasant looking final prod-uct, antioxidants, for example, butylated hydroxy anisole or butylated IO hydroxy toluene, and preservatives, for example, methyl or propyl paraben or sodium benzoate, to prolong and enhance shelf life.
ME~HOD OF T~EATMENT
The amount of the pharmaceutical composition administered depends upon the percent of active ingredients within its formula, which is a IS function of the amount of the naphthalene derivative and any optional componènts such as a decongestant, expectorant and/or antihistamine required per dose, stability, release characteristics and other pharmaceutical parameters.
Usually from about I mg/kg to about 50 mgtkg per day, preferably from about 2 mg/kg to about 30 mg/kg per day and most preferably from about 3 mg/kg per day to about 20 mg~kg per day of the pharmaceutical composition is administered as described herein. This amount can be given in a single dose, or, preferably, in multiple (two to six) doses repeatedly or sustained release dosages over ~he course of treatment.
Generally, each individual dosage of the pharmaceutical comDositions of the present invention range from about I mg/kg to about 25 mg/kg, preferably from about 2 mg/kg to about 15 mg/kg and most preferably from about 3 mg/kg to about IO mg/kg. Typical unit dosage forms for oral auministration generally comprise from about IOO mg to about 2000 mg, preferably from about I50 mg to about 600 mg and most preferably from about I50 mg to about 400 mg of the naphthalene derivative.
While dosages higher than the foregoing are effective to provide relief from cough, cold-like~ flu and flu-like symptoms, care must be taken, as with any drug, in some individuals to prevent adverse side effects.
The fo110wing examples illustrate embodiments of the subject invention wherein both essential and optional ingredients are com-bined.
W O 92/04021 2 0 ~ ~ 2 3 4 Pc~r/usgl/06398 EXAMPLE I
A soft gelatin capsule composition for oral administration is prepared by combining the following ingredients:
Inqredient Amount Naproxen 200 mg Pseudoephedrine HCl 30 mg Triturate active ingredients and q.s. with lactose to selected capsule size.
Administration of two of the above capsules to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE II
A soft gelatin capsule composition for oral administration is prepared by combining the following ingredients:
In~redient Amount Naproxen 200 mg Astemizole 10 mg Pseudoephedrine HCL 30 mg Glyceryl guaiacolate 100 mg Triturate active ingredients and q.s. with lactose to selected capsule size.
Administration of two of the above capsules to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE III
A liquid composition for oral administration is prepared by combining the following ingredients:
Ingredient YO W/V
Naproxen 6.667 Pseudoephedrine HCl 0.200 Alcohol (95X) 25.000 Propylene Glycol 25.000 Sodium Citrate 2.000 Citric Acid 0.250 Liquid Sugar 70.000 Glycerin 7.000 Colorants 0.008 Flavor 0.500 Water, Purified QS 100.000 WO 92/04021 2 ~) 9 ~) 2 3 ~1 PCr/US91/06398 The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid and Pseudoephedrine HCI are added sequen-tially and dissolved with agitation. The glycerin and liquid sugar are then added. In a seperate container the colorance are added to purified water (approximately 0.5% of the final batch volume). This colorance solution is then added to the first batch container. In a seperate container the naproxen is added to the alcohol while stir-ring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.
Administration of 30 ml to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE IV
A liquid composition for oral administration is prepared by combining the following ingredients:
Inqredient % W/V
Naproxen 6.667 Pseudoephedrine HCl 0.200 Chlorpheniramine Maleate 0.013 Alcohol (95~.) 25.000 Propylene Glycol 25.000 Sodium Citrate 2.000 Citric Acid 0.250 Liquid Sugar 70.000 Glycerin 7.000 Colorants 0.008 Flavor O.S00 Water, Purified QS100.000 The purified water (approximately 10Z of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, pseudoephedrine HCI and chlorpheniramine maleate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a seperate container the colorance are added to purified water ~approximately 0.5% of the final WO 92/04021 PCr/US91/06398 batch volume). This colorance solution is then added to the first batch container. In a seperate container the naproxen is added to the alcohol while stirring. The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homo-geneous and then added to the first container. The remaining purifiedwater is added to the resulting mixture and stirred.
Administration of 30 ml to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
EXAMPLE V
A liquid composition for oral administration is prepared by combining the following ingredients:
Inqredient 7O W/V
Naproxen 6.667 1; Pseudoephedrine HCl 0.200 Chlorpheniramine Maleate 0.013 Dextromethorphan HBr 0.100 Alcohol (95%) 25.000 Propylene Glycol 25.000 Sodium Citrate 2.000 Citric Acid 0.250 Liquid Sugar 70.000 Glycerin ~ 7.000 Colorants 0.008 Flavor 0 500 Water, Purified ~S 100.000 The purified water (approximately 10% of the final batch volume) is poured into a batch container equipped with a lightnin' mixer. The sodium citrate, citric acid, pseudoephedrine HCI and chlorpheniramine maleate are added sequentially and dissolved with agitation. The glycerin and liquid sugar are then added. In a seperate container the colorance are added to purified water (approximately 0.5% of the final batch volume). This colorance solution is then added to the first batch container. In a sepera~e container the naproxen and dextro-methorphan HBr are added sequentially to the alcohol while stirring.
L~
W O 92/04021 ~ PC~r/~S91/0~98 2 0 q 0 2 3 4 14 The propylene glycol and flavors are added to this alcohol premix and the resulting mixture is stirred until homogeneous and then added to the first container. The remaining purified water is added to the resulting mixture and stirred.
, Administration of 30 ml to a human in need of treatment provides improved analgesic and/or anti-inflammatory effect.
Claims (14)
1. The use of a composition comprising:
a) from 10% to 95% of a carboxylic acid represented by the following formula:
R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, trifluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene; and R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from 5% to 90% of one or more of a sympathomimetic amine; for producing a medicament for eliciting a sustained, enhanced analgesic response in a human or lower animal in need of such treatment.
a) from 10% to 95% of a carboxylic acid represented by the following formula:
R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, trifluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene; and R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from 5% to 90% of one or more of a sympathomimetic amine; for producing a medicament for eliciting a sustained, enhanced analgesic response in a human or lower animal in need of such treatment.
2. A medicant for eliciting a sustained, enhanced analgesic response in a human or lower animal in need of such treatment comprising:
a) from 10% to 95% of a carboxylic acid represented by the following formula:
R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, tri-fluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkythio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene; and R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from 5% to 90% of one or more of a sympathomimetic amine.
a) from 10% to 95% of a carboxylic acid represented by the following formula:
R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, tri-fluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkythio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene; and R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from 5% to 90% of one or more of a sympathomimetic amine.
3. The medicament of Claim 2 wherein said carboxylic acid derivative is 2-(6.alpha.-methoxy-2-napthyl) propionic acid and pharmaceutically-acceptable salts and esters thereof and is used at a level of from 50 mg to 2000 mg.
4. The medicament of Claim 3 wherein said sympathomimetic amine is selected from the group consisting of pseudoephedrine, phenylpropanolamine, phenylephrine and ephedrine, mixtures thereof or pharmaceutically-acceptable salts thereof.
5. The medicament of Claim 4 wherein the ratio of naphthalene derivative to sympathomimetic amine ranges from 200:1 to 1:1.
6. The medicament of Claim 5 wherein said pharmaceutical medicament further comprises at least one other active component selected from the group consisting of an antihistamine, cough suppressant and expectorant and mixtures thereof.
7. The medicament of Claim 6 wherein said active component is a cough suppressant.
8. The medicament of Claim 6 wherein said active component is an antihistamine.
9. The medicament of Claim 6 wherein said active component is an expectorant.
10. The use of a composition comprising:
a) from 10% to 95% of a carboxylic acid represented by the following formula;
R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, trifluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene; and R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from 5% to 90% of one or more of a sympathomimetic amine; for eliciting a sustained, enhanced analgetic response in a human or lower animal in need of such treatment
a) from 10% to 95% of a carboxylic acid represented by the following formula;
R1 is alkyl having up to 6 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, alkoxymethyl having up to 7 carbon atoms, trifluoromethyl, vinyl, ethynyl, halo (iodo, bromo, chloro or fluoro) alkoxy having up to 6 carbon atoms, difluoromethoxy, alkoxymethoxy having up to 7 carbon atoms, alkylthiomethyloxy having up to 7 carbon atoms, alkylthio having up to 6 carbon atoms, alkoxymethylthio having up to 7 carbon atoms, cyano di-fluoromethylthio, phenyl or alkylsubstituted phenyl having up to 8 carbon atoms; one of R2 and R3 is hydrogen, the other being methyl, ethyl or difluoromethyl or R2 or R3 together are methylene; and R4 is hydrogen, alkyl having up to 22 carbon atoms, unsaturated alkyl having up to 22 carbon atoms, cycloalkyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 3 to 7 carbon atoms, cycloalkylmethyl having from 4 to 9 carbon atoms, 2-cycloalkylethyl having from 5 to 10 carbon atoms, 3-cyclopentylethyl having from 5 to 10 carbon atoms, 3-cyclopentylpropyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl or 3-phenylpropyl; and b) from 5% to 90% of one or more of a sympathomimetic amine; for eliciting a sustained, enhanced analgetic response in a human or lower animal in need of such treatment
11. The medicament of Claim 3 wherein said medicament is used at a level of from 100 mg to 2000 mg.
12. The medicament of Claim 7, wherein the cough suppressant is selected from the group consisting of dextromethorphan, chlophedianol, carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, hydrocodone, hydromorphone, fominoben, mixtures thereof or pharmaceutically acceptable salts thereof.
13. The medicament of Claim 8, wherein the antihistamine is selected from the group consisting of chlorpheniramine brompheniramine, dexchlorpheniramine, dexbromphreniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenhydramine, phenindamine, pyrilamine, azatadine, acrivastine, AHR-11325, phenindamine, astemizole, azatadine, azelastine, cetirizine, ebastine, ketotifen, lodoxamide, loratidine, levocabastine, mequitazine, oxatomide, setastine, tazifylline, temelastine, and terfenadine, mixtures thereof or pharmaceutically acceptable salts thereof.
14. The medicament of Claim 9, wherein the expectorant is an expectorant or mucolytic such as glyceryl guaiacolate, terpin, ammonium chloride, N-acetylcysteine and bromhexine, ambroxol, mixtures thereof or pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58068590A | 1990-09-11 | 1990-09-11 | |
| US580,685 | 1990-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2090234A1 CA2090234A1 (en) | 1992-03-12 |
| CA2090234C true CA2090234C (en) | 1998-08-11 |
Family
ID=24322117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002090234A Expired - Fee Related CA2090234C (en) | 1990-09-11 | 1991-09-09 | Method for providing improved analgesic effect |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPH06500784A (en) |
| KR (1) | KR930701994A (en) |
| AU (1) | AU662297B2 (en) |
| CA (1) | CA2090234C (en) |
| IE (1) | IE913185A1 (en) |
| MA (1) | MA22277A1 (en) |
| MX (1) | MX9101045A (en) |
| PT (1) | PT98919A (en) |
| WO (1) | WO1992004021A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6956494A (en) * | 1993-06-04 | 1995-01-03 | Warner-Lambert Company | Non-alcoholic cold and sinus medication |
| US5626831A (en) * | 1995-12-20 | 1997-05-06 | Van Moerkerken; Arthur | Method for relief and prevention of common cold, and compositions |
| JP4549618B2 (en) * | 2001-11-22 | 2010-09-22 | 第一三共ヘルスケア株式会社 | Composition for rhinitis |
| TWI313598B (en) * | 2002-12-18 | 2009-08-21 | Wyeth Corp | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558051A (en) * | 1983-10-11 | 1985-12-10 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
| US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
-
1991
- 1991-09-09 AU AU85384/91A patent/AU662297B2/en not_active Ceased
- 1991-09-09 WO PCT/US1991/006398 patent/WO1992004021A1/en active Application Filing
- 1991-09-09 CA CA002090234A patent/CA2090234C/en not_active Expired - Fee Related
- 1991-09-09 KR KR1019930700724A patent/KR930701994A/en not_active Ceased
- 1991-09-09 JP JP3515360A patent/JPH06500784A/en active Pending
- 1991-09-10 PT PT98919A patent/PT98919A/en not_active Application Discontinuation
- 1991-09-10 IE IE318591A patent/IE913185A1/en unknown
- 1991-09-10 MA MA22558A patent/MA22277A1/en unknown
- 1991-09-11 MX MX9101045A patent/MX9101045A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT98919A (en) | 1992-07-31 |
| AU662297B2 (en) | 1995-08-31 |
| WO1992004021A1 (en) | 1992-03-19 |
| MA22277A1 (en) | 1992-04-01 |
| KR930701994A (en) | 1993-09-08 |
| AU8538491A (en) | 1992-03-30 |
| MX9101045A (en) | 1992-05-04 |
| IE913185A1 (en) | 1992-03-11 |
| CA2090234A1 (en) | 1992-03-12 |
| JPH06500784A (en) | 1994-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU678561B2 (en) | Pharmaceutical compositions and methods for treating cold symptoms | |
| EP0719156A1 (en) | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive | |
| CA2170485C (en) | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine | |
| AU1989697A (en) | Caffeine and clemastine for treating respiratory disorders | |
| AU8744398A (en) | Compositions and methods for treating respiratory disorders | |
| CA2090234C (en) | Method for providing improved analgesic effect | |
| WO1992004022A1 (en) | Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders | |
| CA2151912A1 (en) | Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders | |
| AU672279B2 (en) | Compositions containing caffeine and S(+)-ibuprofen or S(+)-flurbiprofen or S(+)-ketoprofen | |
| WO1997004808A1 (en) | Compositions containing analgesics and antihistamines and methods for treating respiratory disorders | |
| JP2008115168A (en) | Anti-adenovirus agent | |
| JP4983750B2 (en) | Formulation for oral administration | |
| JP2004339211A (en) | Pharmaceutical composition | |
| JP2004331660A (en) | Pharmaceutical composition | |
| WO2000002545A2 (en) | Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain | |
| JP2004331661A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |